NASDAQ:OBLN - Obalon Therapeutics Stock Price, Forecast & News

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Obalon Therapeutics's stock reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

Obalon Therapeutics Inc (NASDAQ:OBLN) announced its earnings results on Friday, November, 8th. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($3.50) by $2.89. The company earned $0.33 million during the quarter, compared to the consensus estimate of $2.20 million. Obalon Therapeutics had a negative return on equity of 228.96% and a negative net margin of 607.48%. View Obalon Therapeutics' Earnings History.

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Obalon Therapeutics.

4 brokers have issued 12-month price objectives for Obalon Therapeutics' shares. Their forecasts range from $10.00 to $30.00. On average, they anticipate Obalon Therapeutics' stock price to reach $20.63 in the next twelve months. This suggests a possible upside of 997.1% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Obalon Therapeutics.

Media headlines about OBLN stock have trended extremely negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Obalon Therapeutics earned a news impact score of -4.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Obalon Therapeutics.

Some companies that are related to Obalon Therapeutics include PAVmed (PAVM), T2 Biosystems (TTOO), SANUWAVE Health (SNWV), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Co-Diagnostics (CODX), Endologix (ELGX), Neovasc (NVCN), Interpace Diagnostics Group (IDXG), RA Medical Systems (RMED), DarioHealth (DRIO), Biostage (BSTG), Titan Medical (TMDI), Atossa Genetics (ATOS) and Lianluo Smart (LLIT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Actinium Pharmaceuticals (ATNM), Corbus Pharmaceuticals (CRBP), Opko Health (OPK), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Zynerba Pharmaceuticals (ZYNE), Titan Pharmaceuticals (TTNP) and AcelRx Pharmaceuticals (ACRX).

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OBLN stock can currently be purchased for approximately $1.88.

Obalon Therapeutics has a market capitalization of $14.46 million and generates $9.10 million in revenue each year. The company earns $-37,380,000.00 in net income (profit) each year or ($19.60) on an earnings per share basis. Obalon Therapeutics employs 100 workers across the globe.View Additional Information About Obalon Therapeutics.

The official website for Obalon Therapeutics is http://www.obalon.com/.

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]